Differential changes in serotonin 5-HT1A and 5-HT2 receptor binding in patients with chronic schizophrenia
- PMID: 7831439
- DOI: 10.1007/BF02245005
Differential changes in serotonin 5-HT1A and 5-HT2 receptor binding in patients with chronic schizophrenia
Abstract
Serotonin 5-HT1A and 5-HT2 receptors were examined in the postmortem brains of controls and patients with chronic schizophrenia. In the prefrontal cortex from patients with schizophrenia, 5-HT1A receptor binding was increased, while 5-HT2 receptor binding was decreased, when compared to controls. The increased 5-HT1A receptor binding or the decreased 5-HT2 receptor binding was observed in both the patients who had been medicated with neuroleptics at time of death and those who had not, at least 2 months prior to death. Thus, abnormalities of 5-HT receptor subtypes seem to exist in the brains of patients with chronic schizophrenia. 5-HT related agents might be beneficial for the treatment of schizophrenia.
Similar articles
-
Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics.Neuropsychopharmacology. 1993 Jun;8(4):315-36. doi: 10.1038/npp.1993.32. Neuropsychopharmacology. 1993. PMID: 8512620
-
Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia.Life Sci. 1991;48(4):355-63. doi: 10.1016/0024-3205(91)90556-q. Life Sci. 1991. PMID: 1824956
-
5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia.Neuropsychopharmacology. 1996 Nov;15(5):442-55. doi: 10.1016/S0893-133X(96)00053-X. Neuropsychopharmacology. 1996. PMID: 8914117
-
The role of serotonin in schizophrenia: an overview of the nomenclature, distribution and alterations of serotonin receptors in the central nervous system.Psychopharmacology (Berl). 1993;112(1 Suppl):S5-15. doi: 10.1007/BF02245003. Psychopharmacology (Berl). 1993. PMID: 7831440 Review.
-
[The involvement of 5-HT1a serotonin receptors in the pathophysiology and pharmacotherapy of schizophrenia].Psychiatr Pol. 2000 Jul-Aug;34(4):607-21. Psychiatr Pol. 2000. PMID: 11059260 Review. Polish.
Cited by
-
Mechanisms of action of atypical antipsychotic drugs: a critical analysis.Psychopharmacology (Berl). 1996 Mar;124(1-2):2-34. doi: 10.1007/BF02245602. Psychopharmacology (Berl). 1996. PMID: 8935797 Review.
-
The loudness dependence of auditory evoked potentials (LDAEP) as an indicator of serotonergic dysfunction in patients with predominant schizophrenic negative symptoms.PLoS One. 2013 Jul 12;8(7):e68650. doi: 10.1371/journal.pone.0068650. Print 2013. PLoS One. 2013. PMID: 23874705 Free PMC article.
-
Management of the negative symptoms of schizophrenia: new treatment options.CNS Drugs. 2003;17(11):793-823. doi: 10.2165/00023210-200317110-00003. CNS Drugs. 2003. PMID: 12921492
-
Relationship between genetic polymorphisms in the HTR1A gene and paranoid schizophrenia in a northern Han Chinese population.J Mol Neurosci. 2013 Mar;49(3):625-31. doi: 10.1007/s12031-012-9928-9. Epub 2012 Nov 29. J Mol Neurosci. 2013. PMID: 23192369
-
Pharmacological Mechanisms Involved in Sensory Gating Disruption Induced by (±)-3,4-Methylene- Dioxymethamphetamine (MDMA): Relevance to Schizophrenia.Brain Sci. 2020 Jan 13;10(1):44. doi: 10.3390/brainsci10010044. Brain Sci. 2020. PMID: 31941052 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical